Kenta Kambara

611 citations

35 papers · 448 indexed · h-index 13

Geriatrics and Gerontology top 5%
- Sirtuins and Resveratrol in Medicine 2
Oncology
- Lung Cancer Research Studies 11
- Cancer Immunotherapy and Biomarkers 10
- Colorectal Cancer Treatments and Studies 5
Pulmonary and Respiratory Medicine
- Lung Cancer Treatments and Mutations 13
- Chronic Obstructive Pulmonary Disease (COPD) Research 5
Immunology
Physiology
Epidemiology
- Neuroendocrine Tumor Research Advances 5
Pediatrics, Perinatology and Child Health
- Childhood Cancer Survivors' Quality of Life 3

Co-authors: Ryuji Hayashi Kazuyuki Tobe Seisuke Okazawa Minehiko Inomata Shoko Matsui Toshiro Miwa Shingo Imanishi Kensuke Suzuki
Cited by: Geriatrics and Gerontology Oncology Pulmonary and Respiratory Medicine
Journals: PLoS ONE (1 paper)Scientific Reports (1 paper)Journal of Allergy and Clinical Immunology (1 paper)
Partner nations: Japan United States

In The Last Decade

Kenta Kambara

32 papers receiving 442 citations

Peers

Countries citing papers authored by Kenta Kambara

Since Specialization

Citations

This map shows the geographic impact of Kenta Kambara's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kenta Kambara with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kenta Kambara more than expected).

Fields of papers citing papers by Kenta Kambara

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kenta Kambara. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kenta Kambara. The network helps show where Kenta Kambara may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Kenta Kambara, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kenta Kambara Line = papers co-authored together Kenta Kambara links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer Scientific Reports ·Minehiko Inomata,Masahiro Matsumoto,Naoki Takata,Kana Hayashi,Zenta Seto,Takahiro Hirai,Kotaro Tokui,Chihiro Taka,Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Kazuyuki Tobe	2023	10
2	Association of Tumor PD-L1 Expression With Time on Treatment Using EGFR-TKIs in Patients With EGFR-Mutant Non-small Cell Lung Cancer Cancer Diagnosis & Prognosis ·Minehiko Inomata,Masahiro Matsumoto,Isami Mizushima,Zenta Seto,Kana Hayashi,Kotaro Tokui,Chihiro Taka,Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Kazuyuki Tobe	2022	7
3	Immune Checkpoint Inhibitor for Non-small Cell Lung Cancer With Negative or Low Tumor PD-L1 Expression Cancer Diagnosis & Prognosis ·Minehiko Inomata,Naoki Takata,Isami Mizushima,Kenji Azechi,Kana Hayashi,Kotaro Tokui,Chihiro Taka,Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Kazuyuki Tobe	2021	4
4	Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint Inhibitors In Vivo ·Kana Hayashi,Kotaro Tokui,Minehiko Inomata,Kenji Azechi,Isami Mizushima,Naoki Takata,Chihiro Taka,Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Satoshi Nomura,Kazuyuki Tobe	2021	5
5	Irinotecan monotherapy as third- or further-line treatment for patients with small cell lung cancer Tumori Journal ·Zenta Seto,Naoki Takata,Nozomu Murayama,Kotaro Tokui,Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Minehiko Inomata	2020	2
6	Association of Tumor PD-L1 Expression with the T790M Mutation and Progression-Free Survival in Patients with EGFR-Mutant Non-Small Cell Lung Cancer Receiving EGFR-TKI Therapy Diagnostics ·Minehiko Inomata,Kenji Azechi,Naoki Takata,Kana Hayashi,Kotaro Tokui,Chihiro Taka,Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Kazuyuki Tobe	2020	13
7	Peripheral PD1-positive CD4 T-Lymphocyte Count Can Predict Progression-free Survival in Patients With Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitor Anticancer Research ·Minehiko Inomata,Tomonobu Kado,Seisuke Okazawa,Shingo Imanishi,Chihiro Taka,Kenta Kambara,Takahiro Hirai,Hiroaki Tanaka,Kotaro Tokui,Kana Hayashi,Toshiro Miwa,Ryuji Hayashi,Shoko Matsui,Kazuyuki Tobe	2019	26
8	Clinical Parameters for Predicting the Survival in Patients with Squamous and Non-squamous-cell NSCLC Receiving PD-1 Inhibitor Therapy Pathology & Oncology Research ·Minehiko Inomata,Takahiro Hirai,Zenta Seto,Kotaro Tokui,Chihiro Taka,Seisuke Okazawa,Kenta Kambara,Tomomi Ichikawa,Shingo Imanishi,Tōru Yamada,Toshiro Miwa,Ryuji Hayashi,Kazuyuki Tobe	2018	18
9	Clinical Course After Initiation of Nivolumab Therapy in Patients with EGFR-Mutated Non-Small Cell Lung Cancer With or Without Pd-L1 Expression Oncology and Therapy ·Minehiko Inomata,Hiroaki Tanaka,Kotaro Tokui,Chihiro Taka,Seisuke Okazawa,Kenta Kambara,Shingo Imanishi,Toru Yamada,Toshiro Miwa,Ryuji Hayashi,Kazuyuki Tobe	2017	1
10	SIRT1 and FOXO1 mRNA expression in PBMC correlates to physical activity in COPD patients International Journal of COPD ·Chihiro Taka,Ryuji Hayashi,Kazuki Shimokawa,Kotaro Tokui,Seisuke Okazawa,Kenta Kambara,Minehiko Inomata,Toru Yamada,Shoko Matsui,Kazuyuki Tobe	2017	19
11	Relationship between Carnitine Pharmacokinetics and Fatigue in Patients Treated with Cisplatin-Containing Chemotherapy Oncology Research and Treatment ·Tomoaki Ikezaki,Kensuke Suzuki,Kenta Kambara,Minehiko Inomata,Seisuke Okazawa,Shinya Kajiura,Toshiro Miwa,Kouichi Tanabe,Tatsuhiko Kashii	2017	4
12	Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer Anticancer Research ·Minehiko Inomata,Kazuki Shimokawa,Kotaro Tokui,Chihiro Taka,Seisuke Okazawa,Kenta Kambara,Tōru Yamada,Toshiro Miwa,Ryuji Hayashi,Tatsuhiko Kashii,Shoko Matsui,Kazuyuki Tobe	2016	8
13	Elevated levels of plasma lactate dehydrogenase is an unfavorable prognostic factor in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer, receiving treatment with gefitinib or erlotinib Molecular and Clinical Oncology ·Minehiko Inomata,Ryuji Hayashi,Hiroaki Tanaka,Kazuki Shimokawa,Kotaro Tokui,Chihiro Taka,Seisuke Okazawa,Kenta Kambara,Tomomi Ichikawa,Tōru Yamada,Toshiro Miwa,Tatsuhiko Kashii,Shoko Matsui,Kazuyuki Tobe	2016	18
14	Plasma neuron-specific enolase level as a prognostic marker in patients with non-small cell lung cancer receiving gefitinib Molecular and Clinical Oncology ·Minehiko Inomata,Ryuji Hayashi,Azusa Yamamoto,Kotaro Tokui,Chihiro Taka,Seisuke Okazawa,Kenta Kambara,Kensuke Suzuki,Tomomi Ichikawa,Toru Yamada,Toshiro Miwa,Tatsuhiko Kashii,Shoko Matsui,Kazuyuki Tobe,Johji Imura	2015	12
15	Effect of Lung Volume on Airway Luminal Area Assessed by Computed Tomography in Chronic Obstructive Pulmonary Disease PLoS ONE ·Kenta Kambara,Kaoruko Shimizu,Hironi Makita,Masaru Hasegawa,Katsura Nagai,Satoshi Konno,Masaharu Nishimura	2014	17
16	In Vivo Depletion of CD206+ M2 Macrophages Exaggerates Lung Injury in Endotoxemic Mice American Journal Of Pathology ·Kenta Kambara,Wakana Ohashi,Kengo Tomita,Michinori Takashina,Shiho Fujisaka,Ryuji Hayashi,Hisashi Mori,Kazuyuki Tobe,Yuichi Hattori	2014	75
17	Relationship of the urine cortisol level with the performance status of patients with lung cancer: a retrospective study Supportive Care in Cancer ·Kensuke Suzuki,Tomomi Ichikawa,Hideaki Furuse,Takeshi Tsuda,Kotaro Tokui,Yasuaki Masaki,Seisuke Okazawa,Kenta Kambara,Minehiko Inomata,Tōru Yamada,Toshiro Miwa,Shoko Matsui,Tatsuhiko Kashii,Hirokazu Taniguchi,Ryuji Hayashi,Kazuyuki Tobe	2014	3
18	Usefulness of the Palliative Prognostic Index in patients with lung cancer Medical Oncology ·Minehiko Inomata,Ryuji Hayashi,Kotaro Tokui,Chihiro Taka,Seisuke Okazawa,Kenta Kambara,Tomomi Ichikawa,Kensuke Suzuki,Toru Yamada,Toshiro Miwa,Tatsuhiko Kashii,Shoko Matsui,Kazuyuki Tobe	2014	8
19	Sirtuin 1 activator SRT1720 suppresses inflammation in an ovalbumin‐induced mouse model of asthma Respirology ·Tomomi Ichikawa,Ryuji Hayashi,Kensuke Suzuki,Shingo Imanishi,Kenta Kambara,Seisuke Okazawa,Minehiko Inomata,Tōru Yamada,Yu Yamazaki,Yukiko Koshimizu,Toshiro Miwa,Shoko Matsui,Isao Usui,Masaharu Urakaze,Yûji Matsuya,Masakiyo Sasahara,Kazuyuki Tobe	2012	71
20	Visceral adipose tissue level, as estimated by the bioimpedance analysis method, is associated with impaired lung function Journal of Diabetes Investigation ·Minehiko Inomata,Yukio Kawagishi,Chihiro Taka,Kenta Kambara,Seisuke Okazawa,Yasuo Fukushima,Shingo Imanishi,Tomomi Ichikawa,Kensuke Suzuki,Toru Yamada,Yutaka Kamura,Chikaaki Kobashi,Minoru Iwata,Shigeki Sumi,Hideki Origasa,Ryuji Hayashi,Kazuyuki Tobe	2011	14

About Kenta Kambara

Kenta Kambara is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Geriatrics and Gerontology, having authored 35 papers that have together received 448 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (13 papers), Lung Cancer Research Studies (11 papers), Cancer Immunotherapy and Biomarkers (10 papers), Neuroendocrine Tumor Research Advances (5 papers), Colorectal Cancer Treatments and Studies (5 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (5 papers), Childhood Cancer Survivors' Quality of Life (3 papers) and Sirtuins and Resveratrol in Medicine (2 papers). The work is most often cited by research in Geriatrics and Gerontology (62 citations), Oncology (165 citations) and Pulmonary and Respiratory Medicine (160 citations). Kenta Kambara has collaborated with scholars based in Japan and United States. Frequent co-authors include Ryuji Hayashi, Kazuyuki Tobe, Seisuke Okazawa, Minehiko Inomata, Shoko Matsui, Toshiro Miwa, Shingo Imanishi, Kensuke Suzuki, Tatsuhiko Kashii and Tomomi Ichikawa. Their work appears in journals such as PLoS ONE, Scientific Reports and Journal of Allergy and Clinical Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact